SCHEMBL3137674

SCHEMBL3137674

Cc1cc(-c2ccc(N)c(O)c2)cs1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.61
HSD17B10 Q99714 4/20 0.61
ALOX15 P16050 3/20 0.61
BRD4 O60885 1/20 0.47
ALDH1A1 P00352 5/20 0.41
TDP1 Q9NUW8 3/20 0.41
TSHR P16473 2/20 0.41
HSD17B1 P14061 3/20 0.38
HSD17B2 P37059 3/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
KDM4E B2RXH2 3/20 0.37
GAA P10253 3/20 0.37
MAPT P10636 3/20 0.37
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
POLB P06746 2/20 0.37
RAB9A P51151 1/20 0.37
CNR1 P21554 1/20 0.37
HPGD P15428 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3141614 0.79 CYP3A4 (0.61) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL3138220 0.78 HSD17B10 (0.55) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL29549758 0.78 CYP3A4 (1.00) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL105866 0.78 CYP3A4 (1.00) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL29365557 0.78 CYP3A4 (1.00) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL23924225 0.78 CYP3A4 (1.00) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL3466627 0.78 ALDH1A1 (0.43) CYP3A4HSD17B10ALDH1A1TDP1TSHR
SCHEMBL3136343 0.76 ALOX15 (0.57) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
Ammonia Solution, Strong SCHEMBL6653834 0.76 CYP3A4 (0.94) CYP3A4HSD17B10ALOX15BRD4ALDH1A1
SCHEMBL20945278 0.76 ALOX15 (0.94) CYP3A4HSD17B10ALOX15BRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080235882-A1 Novel O-Aminophenol Derivatives and Colorants Containing Said Compounds HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) 2008-10-02 US claimed
CN-1997637-A Novel o-aminophenol derivatives and colorants containing said compounds WELLA AG (DE) 2007-07-11 CN claimed
EP-1768971-A1 NOVEL O-AMINOPHENOL DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS Wella Aktiengesellschaft (DE) 2007-04-04 EP claimed
WO-2006007896-A1 NOVEL O-AMINOPHENOL DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS WELLA AKTIENGESELLSCHAFT (DE) 2006-01-26 WO claimed
US-7641702-B2 O-Aminophenol derivatives and colorants containing said compounds WELLA AG (DE) 2010-01-05 US disclosed
US-20080235882-A1 Novel O-Aminophenol Derivatives and Colorants Containing Said Compounds HFC PRESTIGE INTERNATIONAL OPERATIONS SWITZERLAND SÀRL (CH) 2008-10-02 US disclosed
CN-1997637-A Novel o-aminophenol derivatives and colorants containing said compounds WELLA AG (DE) 2007-07-11 CN disclosed
EP-1768971-A1 NOVEL O-AMINOPHENOL DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS Wella Aktiengesellschaft (DE) 2007-04-04 EP disclosed
WO-2006007896-A1 NOVEL O-AMINOPHENOL DERIVATIVES AND COLORANTS CONTAINING SAID COMPOUNDS WELLA AKTIENGESELLSCHAFT (DE) 2006-01-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080235882-A1 Novel O-Aminophenol Derivatives and Colorants Containing Said Compounds CBR3, KRT18, F12 CYP3A4 526/4885HSD17B10 2013/4885ALOX15 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.